BioMarin Pharmaceutical Inc. Stock Forecast
Green day on Friday for BioMarin Pharmaceutical Inc.
(Updated on Mar 24, 2023)
The BioMarin Pharmaceutical Inc. stock price gained 0.699% on the last trading day (Friday, 24th Mar 2023), rising from $90.11 to $90.74. During the last trading day the stock fluctuated 2.04% from a day low at $89.34 to a day high of $91.16. The price has been going up and down for this period, and there has been a 0.28% gain for the last 2 weeks. Volume fell on the last day by -473 thousand shares and in total, 772 thousand shares were bought and sold for approximately $70.04 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
Build a recession-proof portfolio with your existing stocks. Register to free live event. Ad
The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -16.63% during the next 3 months and, with a 90% probability hold a price between $71.14 and $86.55 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.
BMRN Signals & Forecast
A buy signal was issued from a pivot bottom point on Wednesday, March 15, 2023, and so far it has risen 3.42%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely. Some negative signals were issued as well, and these may have some influence on the near short-term development. The BioMarin Pharmaceutical Inc. stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $91.49 and $100.04. A break-up above any of these levels will issue buy signals.
Support, Risk & Stop-loss for BioMarin Pharmaceutical Inc. stock
BioMarin Pharmaceutical Inc. finds support from accumulated volume at $90.49 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $1.82 between high and low, or 2.04%. For the last week, the stock has had daily average volatility of 2.22%.
Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.
Trading Expectations (BMRN) For The Upcoming Trading Day Of Monday 27th
For the upcoming trading day on Monday, 27th we expect BioMarin Pharmaceutical Inc. to open at $90.41, and during the day (based on 14 day Average True Range), to move between $88.08 and $93.40, which gives a possible trading interval of +/-$2.66 (+/-2.93%) up or down from last closing price. If BioMarin Pharmaceutical Inc. takes out the full calculated possible swing range there will be an estimated 5.85% move between the lowest and the highest trading price during the day.
Since the stock is closer to the support from accumulated volume at $90.49 (0.28%) than the resistance at $93.41 (2.94%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..
Is BioMarin Pharmaceutical Inc. stock A Buy?
BioMarin Pharmaceutical Inc. holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Current score: -2.540 Open Broker Account
Sell Candidate UnchangedPredicted Opening Price for BioMarin Pharmaceutical Inc. of Monday, March 27, 2023
The predicted opening price is based on yesterday's movements between high, low, and closing price.
| Fair opening price March 27, 2023 | Current price |
|---|---|
| $90.41 | $90.74 (Overvalued) |
Remember To Visit Our YouTube Channel
Trading levels for BMRN
Fibonacci Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 92.23 | 1.65 % | |
| R2 | 91.54 | 0.88 % | ||
| R1 | 91.11 | 0.406 % | ||
| Current price: | 90.74 | |||
| Support | S1 | 89.72 | -1.13 % | |
| S2 | 89.29 | -1.60 % | ||
| S3 | 88.59 | -2.37 % |
Accumulated Volume Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 111.40 | 22.77 % | |
| R2 | 94.30 | 3.92 % | ||
| R1 | 93.41 | 2.94 % | ||
| Current price | 90.74 | |||
| Support | S1 | 90.49 | -0.276% | |
| S2 | 90.25 | -0.540% | ||
| S3 | 90.02 | -0.793% |
FAQ
Click here for our free guide on how to buy BioMarin Pharmaceutical Inc. Stock.
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form o... BMRN Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
